LeJeune Puetz Investment Counsel LLC Invests $1.846 Million in Amgen, Inc. (AMGN)

LeJeune Puetz Investment Counsel LLC acquired a new position in Amgen, Inc. (NASDAQ:AMGN) during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 12,623 shares of the medical research company’s stock, valued at approximately $1,846,000. Amgen makes up approximately 1.4% of LeJeune Puetz Investment Counsel LLC’s portfolio, making the stock its 18th largest position.

Other hedge funds and other institutional investors also recently modified their holdings of the company. New York Life Trust Co. boosted its position in Amgen by 54.8% in the third quarter. New York Life Trust Co. now owns 624 shares of the medical research company’s stock valued at $104,000 after buying an additional 221 shares during the last quarter. Penserra Capital Management LLC boosted its position in Amgen by 100.0% in the third quarter. Penserra Capital Management LLC now owns 684 shares of the medical research company’s stock valued at $114,000 after buying an additional 342 shares during the last quarter. Oakworth Capital Inc. boosted its position in Amgen by 1.4% in the third quarter. Oakworth Capital Inc. now owns 711 shares of the medical research company’s stock valued at $119,000 after buying an additional 10 shares during the last quarter. Focused Wealth Management Inc boosted its position in Amgen by 248.0% in the fourth quarter. Focused Wealth Management Inc now owns 870 shares of the medical research company’s stock valued at $127,000 after buying an additional 620 shares during the last quarter. Finally, Northwest Quadrant Wealth Management LLC acquired a new position in Amgen during the fourth quarter valued at about $157,000. Hedge funds and other institutional investors own 79.04% of the company’s stock.

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Shares of Amgen, Inc. (NASDAQ:AMGN) traded up 0.61% on Thursday, hitting $162.25. The stock had a trading volume of 752,942 shares. The firm’s 50 day moving average is $169.48 and its 200-day moving average is $158.65. Amgen, Inc. has a one year low of $133.64 and a one year high of $184.21. The stock has a market capitalization of $119.49 billion, a PE ratio of 15.84 and a beta of 1.15.

Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Thursday, February 2nd. The medical research company reported $2.89 earnings per share for the quarter, beating analysts’ consensus estimates of $2.79 by $0.10. Amgen had a net margin of 33.59% and a return on equity of 29.42%. The business earned $5.97 billion during the quarter, compared to analyst estimates of $5.75 billion. During the same period in the previous year, the business earned $2.61 EPS. Amgen’s revenue was up 7.7% compared to the same quarter last year. Equities research analysts expect that Amgen, Inc. will post $12.33 earnings per share for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Thursday, June 8th. Stockholders of record on Wednesday, May 17th will be given a dividend of $1.15 per share. The ex-dividend date of this dividend is Monday, May 15th. This represents a $4.60 dividend on an annualized basis and a dividend yield of 2.85%. Amgen’s dividend payout ratio (DPR) is currently 44.92%.

COPYRIGHT VIOLATION WARNING: This piece was originally posted by Chaffey Breeze and is the property of of Chaffey Breeze. If you are viewing this piece on another domain, it was illegally copied and republished in violation of United States & international trademark & copyright legislation. The correct version of this piece can be accessed at https://www.chaffeybreeze.com/2017/04/20/lejeune-puetz-investment-counsel-llc-acquires-new-position-in-amgen-inc-amgn-updated.html.

Several research analysts recently weighed in on the company. Mizuho set a $195.00 target price on Amgen and gave the company a “buy” rating in a research note on Friday, March 10th. Vetr cut Amgen from a “hold” rating to a “sell” rating and set a $174.10 target price for the company. in a research note on Monday, March 13th. Piper Jaffray Companies reaffirmed an “overweight” rating and set a $193.00 target price on shares of Amgen in a research note on Tuesday, March 14th. Oppenheimer Holdings Inc. reaffirmed an “outperform” rating and set a $189.00 target price on shares of Amgen in a research note on Tuesday, March 14th. Finally, BMO Capital Markets reaffirmed an “outperform” rating and set a $212.00 target price on shares of Amgen in a research note on Monday, March 6th. One investment analyst has rated the stock with a sell rating, ten have given a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $186.94.

Amgen Company Profile

Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).

5 Day Chart for NASDAQ:AMGN

Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply